| HNVIX | VSIAX | HNVIX / VSIAX | |
| Total Expense Ratio | 0.94 | 0.07 | 1,343% |
| Annual Report Gross Expense Ratio | 0.94 | 0.07 | 1,343% |
| Fund Existence | 18 years | 14 years | - |
| Gain YTD | -1.294 | 5.811 | -22% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 500000 | 3000 | 16,667% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 287M | 58.3B | 0% |
| Annual Yield % from dividends | 0.78 | 2.02 | 38% |
| Returns for 1 year | -10.59 | -0.53 | 1,988% |
| Returns for 3 years | -4.37 | 27.41 | -16% |
| Returns for 5 years | 4.19 | 65.19 | 6% |
| Returns for 10 years | 38.84 | 117.18 | 33% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FBBYX | 27.74 | -0.16 | -0.57% |
| First Foundation Total Return Y | |||
| TCEMX | 13.51 | -0.09 | -0.66% |
| Templeton Emerging Markets Small Cap C | |||
| FTDZX | 176.95 | -2.17 | -1.21% |
| Franklin Biotechnology Discovery Adv | |||
| TRULX | 45.81 | -0.70 | -1.51% |
| T. Rowe Price US Large-Cap Core | |||
| QIACX | 53.65 | -0.92 | -1.69% |
| Federated Hermes MDT All Cap Core IS | |||